A Population-Based Cohort Defined Risk of Hyperkalemia after Initiating SGLT-2 Inhibitors, GLP1 Receptor Agonists or DPP-4 Inhibitors to Patients with Chronic Kidney Disease and Type 2 Diabetes.

Edouard L. Fu,Julianna Mastrorilli,Katsiaryna Bykov,Deborah J. Wexler,Alexander Cervone,Kueiyu Joshua Lin,Elisabetta Patorno, Julie M. Paik

KIDNEY INTERNATIONAL（2024）

引用 0|浏览42

暂无评分

关键词

chronic kidney disease,dipeptidyl peptidase-4 inhibitors,glucagon-like peptide-1 receptor agonists,hyperkalemia,sodium-glucose cotransporter-2 inhibitors,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要